Celyad Oncology S.A.
CYAD
Rankning i aktier
#31681
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Aktiekurs
$0.24909259
Marknadsvärde
$11.77M
Förändring (1 dag)
1.94%
Förändring (1 år)
-47.00%
Land
BE
Handel Celyad Oncology S.A. (CYAD)
Kategori
Healthcare
Utdelningsavkastning för Celyad Oncology S.A. (CYAD)
Utdelningsavkastningen (TTM) för Celyad Oncology S.A. (aktiesymbol: CYAD) per 2026 är: 0
Genomsnittlig utdelningsavkastning de senaste 5 åren: 0.00%
Genomsnittlig utdelningsavkastning de senaste 5 åren: 0.00%
Historik för utdelningsavkastning för Celyad Oncology S.A. (CYAD) från 2026 till 2026
Utdelningsavkastning i slutet av varje år (TTM)
| År | Utdelningsavkastning | Ändra |
|---|---|---|
| Inte tillräckligt med data för de angivna datumen. | ||
Utdelningsavkastning (TTM) för liknande företag eller konkurrenter
| Företag | Utdelningsavkastning | Land |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
